WO1998011888A1
(en)
*
|
1996-09-19 |
1998-03-26 |
American Home Products Corporation |
Method of treating urinary incontinence
|
US20100137358A1
(en)
*
|
1996-11-05 |
2010-06-03 |
Dr. Reddy's Laboratories Ltd. |
Solifenacin compositions
|
IL141235A
(en)
*
|
2000-02-09 |
2012-04-30 |
Novartis Int Pharm Ltd |
Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
|
US7858119B1
(en)
*
|
2000-05-09 |
2010-12-28 |
Amina Odidi |
Extended release pharmaceuticals
|
US6653339B2
(en)
|
2001-08-15 |
2003-11-25 |
Pfizer Inc. |
Method of treating irritable bowel syndrome
|
DE10149674A1
(de)
*
|
2001-10-09 |
2003-04-24 |
Apogepha Arzneimittel Gmbh |
Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
|
US7163696B2
(en)
*
|
2001-10-11 |
2007-01-16 |
Pfizer Inc. |
Pharmaceutical formulations
|
US8329217B2
(en)
|
2001-11-06 |
2012-12-11 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
Dual controlled release dosage form
|
US20030185882A1
(en)
*
|
2001-11-06 |
2003-10-02 |
Vergez Juan A. |
Pharmaceutical compositions containing oxybutynin
|
GB0129962D0
(en)
|
2001-12-14 |
2002-02-06 |
Pfizer Ltd |
Method of treatment
|
GB0207104D0
(en)
|
2002-03-26 |
2002-05-08 |
Pfizer Ltd |
Stable hydrate of a muscarinic receptor antagonist
|
CA2451267A1
(en)
*
|
2002-12-13 |
2004-06-13 |
Warner-Lambert Company Llc |
Pharmaceutical uses for alpha2delta ligands
|
ES2341240T3
(es)
|
2002-12-13 |
2010-06-17 |
Warner-Lambert Company Llc |
Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
|
US20040235857A1
(en)
*
|
2003-02-11 |
2004-11-25 |
Pfizer Inc |
Crystalline therapeutic agent
|
PA8597401A1
(es)
*
|
2003-03-14 |
2005-05-24 |
Pfizer |
Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
|
US20040186046A1
(en)
*
|
2003-03-17 |
2004-09-23 |
Pfizer Inc |
Treatment of type 1 diabetes with PDE5 inhibitors
|
EA008596B1
(ru)
|
2003-04-29 |
2007-06-29 |
Пфайзер Инк. |
5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
|
US7268147B2
(en)
*
|
2003-05-15 |
2007-09-11 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
WO2004112756A1
(en)
|
2003-06-26 |
2004-12-29 |
Isa Odidi |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
US20050043300A1
(en)
*
|
2003-08-14 |
2005-02-24 |
Pfizer Inc. |
Piperazine derivatives
|
PL1664036T3
(pl)
*
|
2003-09-03 |
2012-04-30 |
Pfizer |
Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4
|
EP1663398B1
(en)
|
2003-09-12 |
2009-11-25 |
Pfizer Limited |
Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors
|
WO2005033107A1
(en)
*
|
2003-10-03 |
2005-04-14 |
Pfizer Limited |
Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation
|
GB0327323D0
(en)
*
|
2003-11-24 |
2003-12-31 |
Pfizer Ltd |
Novel pharmaceuticals
|
US7572799B2
(en)
*
|
2003-11-24 |
2009-08-11 |
Pfizer Inc |
Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
|
US7649002B2
(en)
|
2004-02-04 |
2010-01-19 |
Pfizer Inc |
(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
|
GB0402491D0
(en)
*
|
2004-02-04 |
2004-03-10 |
Pfizer Ltd |
Medicaments
|
US7629358B2
(en)
*
|
2004-03-17 |
2009-12-08 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
CA2560510C
(en)
*
|
2004-03-18 |
2009-10-13 |
Pfizer Inc. |
N-(1-arylpyrazol-4yl) sulfonamides and their use as parasiticides
|
US7538141B2
(en)
*
|
2004-03-23 |
2009-05-26 |
Alan Daniel Brown |
Compounds for the treatment of diseases
|
AU2005225632B2
(en)
*
|
2004-03-23 |
2011-08-04 |
Pfizer Inc. |
Formamide derivatives useful as adrenoceptor
|
US20050215542A1
(en)
*
|
2004-03-23 |
2005-09-29 |
Pfizer Inc |
Compounds for the treatment of diseases
|
DK1742950T3
(da)
*
|
2004-04-07 |
2009-03-16 |
Pfizer Ltd |
Pyrazolo-[4,3-D]-pyrimidiner
|
KR100875558B1
(ko)
*
|
2004-06-15 |
2008-12-23 |
화이자 인코포레이티드 |
벤즈이미다졸론 카복실산 유도체
|
US7737163B2
(en)
*
|
2004-06-15 |
2010-06-15 |
Pfizer Inc. |
Benzimidazolone carboxylic acid derivatives
|
US8394409B2
(en)
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
DE602005010714D1
(de)
*
|
2004-08-12 |
2008-12-11 |
Pfizer |
Der p38-map-kinase
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
EA011725B1
(ru)
*
|
2004-08-26 |
2009-04-28 |
Пфайзер Инк. |
Пиразолзамещённые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
|
ME01788B
(me)
|
2004-08-26 |
2011-02-28 |
Pfizer |
Enantiomerno čista aminoheteroaril jedinjenja kao inhibitori protein kinaza
|
JP2008518905A
(ja)
*
|
2004-11-02 |
2008-06-05 |
ファイザー株式会社 |
スルホニルベンゾイミダゾール誘導体
|
US20060111416A1
(en)
*
|
2004-11-24 |
2006-05-25 |
Lane Charlotte A L |
Octahydropyrrolo[3,4-C]pyrrole derivatives
|
AP2007004157A0
(en)
|
2005-03-17 |
2007-10-31 |
Pfizer |
N- (N-sulfonylaminomethyl) cyclo-propanecarboxamide derivatives useful for the treatment of pain
|
CA2602566A1
(en)
*
|
2005-03-28 |
2006-10-05 |
Pfizer Inc. |
Substituted aryloxoethyl cyclopropanecarboxamide compounds as vr1 receptor antagonists
|
US20080176865A1
(en)
*
|
2005-06-15 |
2008-07-24 |
Pfizer Limited |
Substituted arylpyrazoles
|
US20080146643A1
(en)
*
|
2005-06-15 |
2008-06-19 |
Pfizer Limited |
Combination
|
US20070149464A1
(en)
*
|
2005-06-15 |
2007-06-28 |
Pfizer Inc. |
Combination
|
US7645786B2
(en)
*
|
2005-06-15 |
2010-01-12 |
Pfizer Inc. |
Substituted arylpyrazoles
|
DE602006012042D1
(de)
*
|
2005-06-15 |
2010-03-18 |
Pfizer Ltd |
Substituierte arylpyrazole zur verwendung gegen parasiten
|
JP2009503050A
(ja)
*
|
2005-08-04 |
2009-01-29 |
ファイザー・リミテッド |
ピペリジノイル−ピロリジンおよびピペリジノイル−ピペリジン化合物
|
WO2007017752A1
(en)
*
|
2005-08-10 |
2007-02-15 |
Pfizer Limited |
Substituted triazole derivatives as oxytocin antagonists
|
BRPI0615432A2
(pt)
|
2005-09-02 |
2011-05-17 |
Theravida Inc |
composição farmacêutica, e, uso de compostos
|
CA2547216A1
(en)
|
2005-09-21 |
2007-03-21 |
Renuka D. Reddy |
Process for annealing amorphous atorvastatin
|
NL2000323C2
(nl)
|
2005-12-20 |
2007-11-20 |
Pfizer Ltd |
Pyrimidine-derivaten.
|
US20070141684A1
(en)
|
2005-12-21 |
2007-06-21 |
Pfizer Inc |
Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
US20090062326A1
(en)
*
|
2006-03-17 |
2009-03-05 |
Spindel Eliot R |
M3 muscarinic receptor antagonists for treatment of m3 muscarinic receptor-expressing tumors
|
CA2648280C
(en)
|
2006-04-03 |
2014-03-11 |
Isa Odidi |
Controlled release delivery device comprising an organosol coat
|
EP2021338A1
(en)
|
2006-05-09 |
2009-02-11 |
Pfizer Products Inc. |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
US20100256357A1
(en)
*
|
2006-08-09 |
2010-10-07 |
Agouron Pharmaceuticals, Inc. |
Heterocycles useful as inhibitors of carbonic anhydrase
|
WO2008031221A1
(en)
*
|
2006-09-12 |
2008-03-20 |
Cephalin Pharmaceuticals Inc. |
Isovaline for treatment of pain
|
ATE512969T1
(de)
*
|
2006-09-21 |
2011-07-15 |
Raqualia Pharma Inc |
Benzimidazolderivate als selektive säurepumpenhemmer
|
WO2008050199A2
(en)
|
2006-10-23 |
2008-05-02 |
Pfizer Japan Inc. |
Substituted phenylmethyl bicyclocarboxyamide compounds
|
UA94639C2
(ru)
*
|
2007-02-02 |
2011-05-25 |
Пфайзер Продактс Інк. |
Трициклические соединения и их применение как модуляторов глюкокортикоидного рецептора
|
US20100216823A1
(en)
*
|
2007-05-24 |
2010-08-26 |
Pfizer Inc. |
Spirocyclic Derivatives
|
CN101084891A
(zh)
*
|
2007-06-29 |
2007-12-12 |
北京本草天源药物研究院 |
一种用于口服的达非那新或其药用盐的药物制剂
|
WO2009006413A1
(en)
*
|
2007-06-30 |
2009-01-08 |
Auspex Pharmaceuticals, Inc. |
Substituted pyrrolidines
|
US8323695B2
(en)
|
2007-08-13 |
2012-12-04 |
Mcneil-Ppc, Inc. |
Method for stabilizing phenylephrine
|
CZ200845A3
(cs)
*
|
2008-01-28 |
2009-09-02 |
Zentiva, A. S. |
Zpusob prípravy Darifenacinu
|
WO2009105887A1
(en)
*
|
2008-02-26 |
2009-09-03 |
Ernest Puil |
Cyclic amino acids for the treatment of pain
|
WO2009139470A1
(ja)
*
|
2008-05-16 |
2009-11-19 |
学校法人聖マリアンナ医科大学 |
線維筋痛症治療用医薬組成物
|
WO2009140078A1
(en)
*
|
2008-05-16 |
2009-11-19 |
The Procter & Gamble Company |
Treatment of lower urinary tract dysfunction with cb2-receptor-selective agonists
|
BRPI0912161A2
(pt)
*
|
2008-05-30 |
2015-10-06 |
Ucb Pharma Sa |
composição farmacêutica na forma de um tablete
|
ES2378513T3
(es)
*
|
2008-08-06 |
2012-04-13 |
Pfizer Inc. |
Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
|
EP2163253B1
(en)
|
2008-09-15 |
2013-07-17 |
ULLRICH, Oliver |
Extracts from the plant Hornstedtia scyphifera and immunosuppressive effects thereof
|
JP5621148B2
(ja)
|
2008-11-21 |
2014-11-05 |
ラクオリア創薬株式会社 |
5−ht2b受容体拮抗活性を有する新規ピラゾール−3−カルボキサミド誘導体
|
RS53941B1
(en)
|
2009-01-12 |
2015-08-31 |
Pfizer Limited |
SULFONAMID DERIVATIVES
|
EP2406281B1
(en)
|
2009-03-12 |
2016-02-17 |
Haase Investments UG |
Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity
|
EP2233502A1
(en)
|
2009-03-27 |
2010-09-29 |
Deutsches Rheuma-Forschungszentrum Berlin |
Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
|
EP2236516A1
(en)
|
2009-03-31 |
2010-10-06 |
Charité-Universitätsmedizin Berlin (Charité) |
Polypeptides and use thereof for treatment of traumatic or degenerative neuronal injury
|
CA2760284A1
(en)
|
2009-05-29 |
2010-12-02 |
Pfizer Limited |
Novel glucocorticoid receptor agonists
|
EP2266563A1
(en)
|
2009-06-11 |
2010-12-29 |
Charité-Universitätsmedizin Berlin (Charité) |
Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
|
WO2011004276A1
(en)
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
US8617763B2
(en)
*
|
2009-08-12 |
2013-12-31 |
Bloom Energy Corporation |
Internal reforming anode for solid oxide fuel cells
|
EP2509978A1
(en)
|
2009-12-11 |
2012-10-17 |
E.I. Du Pont De Nemours And Company |
Azocyclic inhibitors of fatty acid amide hydrolase
|
WO2011077313A1
(en)
|
2009-12-22 |
2011-06-30 |
Pfizer Inc. |
Piperidinecarboxamides as mpges - 1 inhibitors
|
PE20130188A1
(es)
|
2009-12-23 |
2013-02-21 |
Takeda Pharmaceutical |
Pirrolidinonas heteroaromaticas fusionadas como inhibidores de syk
|
SG174658A1
(en)
|
2010-04-01 |
2011-10-28 |
Theravida Inc |
Pharmaceutical formulations for the treatment of overactive bladder
|
CA2796967C
(en)
|
2010-05-04 |
2015-12-01 |
Pfizer Inc. |
Heterocyclic derivatives as alk inhibitors
|
WO2011154871A1
(en)
|
2010-06-10 |
2011-12-15 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
WO2011161504A1
(en)
*
|
2010-06-23 |
2011-12-29 |
Micro Labs Limited |
Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof
|
JP5860045B2
(ja)
|
2010-07-09 |
2016-02-16 |
ファイザー・リミテッドPfizer Limited |
化合物
|
CA2804173C
(en)
|
2010-07-09 |
2015-01-13 |
Pfizer Limited |
Sulfonamide nav1.7 inhibitors
|
JP5830534B2
(ja)
|
2010-07-09 |
2015-12-09 |
ファイザー・リミテッドPfizer Limited |
化合物
|
WO2012007877A2
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Chemical compounds
|
ES2526981T3
(es)
|
2010-07-12 |
2015-01-19 |
Pfizer Limited |
N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
|
JP2013532184A
(ja)
|
2010-07-12 |
2013-08-15 |
ファイザー・リミテッド |
電位開口型ナトリウムチャネル阻害剤として有用なn−スルホニルベンズアミド誘導体
|
US9096500B2
(en)
|
2010-07-12 |
2015-08-04 |
Pfizer Limited |
Acyl sulfonamide compounds
|
WO2012007883A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
JP5902704B2
(ja)
|
2010-11-15 |
2016-04-13 |
ヴィーブ ヘルスケア ユーケー リミテッド |
Hiv複製の阻害剤
|
EP2457900A1
(en)
|
2010-11-25 |
2012-05-30 |
Almirall, S.A. |
New pyrazole derivatives having CRTh2 antagonistic behaviour
|
EP2463289A1
(en)
|
2010-11-26 |
2012-06-13 |
Almirall, S.A. |
Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
|
CN102048706B
(zh)
*
|
2011-01-12 |
2012-02-22 |
山东创新药物研发有限公司 |
一种氢溴酸达非那新缓释片及制备方法
|
WO2012095781A1
(en)
|
2011-01-13 |
2012-07-19 |
Pfizer Limited |
Indazole derivatives as sodium channel inhibitors
|
EP2489663A1
(en)
|
2011-02-16 |
2012-08-22 |
Almirall, S.A. |
Compounds as syk kinase inhibitors
|
AR085406A1
(es)
|
2011-02-25 |
2013-09-25 |
Takeda Pharmaceutical |
Oxazinopteridinas y oxazinopteridinonas n-sustituidas
|
WO2012120398A1
(en)
|
2011-03-04 |
2012-09-13 |
Pfizer Limited |
Aryl substituted carboxamide derivatives as trpm8 modulators
|
MX2013011612A
(es)
|
2011-04-05 |
2013-10-17 |
Pfizer Ltd |
Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasa relacionados con tropomiosina.
|
EP2518070A1
(en)
|
2011-04-29 |
2012-10-31 |
Almirall, S.A. |
Pyrrolotriazinone derivatives as PI3K inhibitors
|
EP2518071A1
(en)
|
2011-04-29 |
2012-10-31 |
Almirall, S.A. |
Imidazopyridine derivatives as PI3K inhibitors
|
US20120289562A1
(en)
|
2011-05-10 |
2012-11-15 |
Theravida, Inc. |
Combinations of darifenacin and salivary stimulants for the treatment of overactive bladder
|
RU2671575C2
(ru)
|
2011-05-10 |
2018-11-02 |
Теравида, Инк. |
Применение солифенацина и стимуляторов слюноотделения в лечении гиперактивного мочевого пузыря
|
EP2710002B1
(en)
|
2011-05-18 |
2017-03-01 |
RaQualia Pharma Inc |
Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
|
EP2527344A1
(en)
|
2011-05-25 |
2012-11-28 |
Almirall, S.A. |
Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
|
EP2526945A1
(en)
|
2011-05-25 |
2012-11-28 |
Almirall, S.A. |
New CRTH2 Antagonists
|
US9056873B2
(en)
|
2011-06-22 |
2015-06-16 |
Takeda Pharmaceutical Company Limited |
Substituted 6-aza-isoindolin-1-one derivatives
|
EP2548863A1
(en)
|
2011-07-18 |
2013-01-23 |
Almirall, S.A. |
New CRTh2 antagonists.
|
EP2548876A1
(en)
|
2011-07-18 |
2013-01-23 |
Almirall, S.A. |
New CRTh2 antagonists
|
US8575336B2
(en)
|
2011-07-27 |
2013-11-05 |
Pfizer Limited |
Indazoles
|
EP2554544A1
(en)
|
2011-08-01 |
2013-02-06 |
Almirall, S.A. |
Pyridin-2(1h)-one derivatives as jak inhibitors
|
MX2014001354A
(es)
|
2011-08-02 |
2014-10-14 |
Pfizer |
Crizotinib para uso en el tratamiento de cancer.
|
WO2013054185A1
(en)
|
2011-10-13 |
2013-04-18 |
Pfizer, Inc. |
Pyrimidine and pyridine derivatives useful in therapy
|
JP2014530849A
(ja)
|
2011-10-19 |
2014-11-20 |
ゾエティス・エルエルシー |
内部寄生虫に対するアミノアセトニトリル誘導体の使用
|
JP5363636B2
(ja)
|
2011-10-21 |
2013-12-11 |
ファイザー・リミテッド |
新規な塩および医学的使用
|
CN103906746B
(zh)
|
2011-10-26 |
2015-12-09 |
辉瑞有限公司 |
用作钠通道调节剂的(4-苯基咪唑-2-基)乙胺衍生物
|
WO2013061297A1
(en)
|
2011-10-28 |
2013-05-02 |
Pfizer Limited |
Pyridazine Derivatives Useful in Therapy
|
US9085517B2
(en)
|
2011-12-15 |
2015-07-21 |
Pfizer Limited |
Sulfonamide derivatives
|
WO2013093688A1
(en)
|
2011-12-19 |
2013-06-27 |
Pfizer Limited |
Sulfonamide derivatives and use thereof as vgsc inhibitors
|
CN102579379B
(zh)
*
|
2011-12-29 |
2016-08-10 |
北京科信必成医药科技发展有限公司 |
一种药物缓释制剂及其制备方法
|
CN102600096B
(zh)
*
|
2011-12-29 |
2016-08-10 |
北京科信必成医药科技发展有限公司 |
一种达非那新缓释制剂及其制备方法
|
JP6067031B2
(ja)
|
2012-01-04 |
2017-01-25 |
ファイザー・リミテッドPfizer Limited |
N−アミノスルホニルベンズアミド
|
CA2861439C
(en)
|
2012-02-03 |
2016-07-12 |
Pfizer Inc. |
Benzimidazole and imidazopyridine derivatives as sodium channel modulators
|
MD4590C1
(ro)
|
2012-03-06 |
2019-03-31 |
Pfizer Inc. |
Derivaţi macrociclici pentru tratamentul bolilor proliferative
|
US9365566B2
(en)
|
2012-03-27 |
2016-06-14 |
Takeda Pharmaceutical Company Limited |
Cinnoline derivatives
|
WO2013152135A1
(en)
|
2012-04-04 |
2013-10-10 |
Dawei Zhang |
Substituted quinolines as bruton's tyrosine kinases inhibitors
|
UY34893A
(es)
|
2012-07-10 |
2014-02-28 |
Takeda Pharmaceutical |
Derivados de azaindol
|
US9475816B2
(en)
|
2012-09-07 |
2016-10-25 |
Takeda Pharmaceutical Company Limited |
Substituted-1,4-dihydropyrazolo[4,3-b]indoles
|
CA2884921A1
(en)
|
2012-09-18 |
2014-03-27 |
Ziarco Pharma Ltd |
2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors
|
US20150239842A1
(en)
|
2012-09-28 |
2015-08-27 |
Pfizer Inc. |
Benzamide and heterobenzamide compounds
|
WO2014053967A1
(en)
|
2012-10-04 |
2014-04-10 |
Pfizer Limited |
Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
|
CA2885259A1
(en)
|
2012-10-04 |
2014-04-10 |
Pfizer Limited |
Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
|
EP2903986A1
(en)
|
2012-10-04 |
2015-08-12 |
Pfizer Limited |
Tropomyosin-related kinase inhibitors
|
WO2014060431A1
(en)
|
2012-10-16 |
2014-04-24 |
Almirall, S.A. |
Pyrrolotriazinone derivatives as pi3k inhibitors
|
KR101660664B1
(ko)
|
2012-11-08 |
2016-09-27 |
화이자 인코포레이티드 |
도파민 d1 리간드로서의 헤테로방향족 화합물
|
RU2617842C2
(ru)
|
2012-11-08 |
2017-04-28 |
Пфайзер Инк. |
Гетероароматические соединения и их применение в качестве допаминовых D1 лигандов
|
WO2014080633A1
(en)
|
2012-11-21 |
2014-05-30 |
Raqualia Pharma Inc. |
Polymorph forms
|
DK2925725T3
(en)
|
2012-12-03 |
2017-01-16 |
Pfizer |
androgen receptor modulators
|
UA112028C2
(uk)
|
2012-12-14 |
2016-07-11 |
Пфайзер Лімітед |
Похідні імідазопіридазину як модулятори гамка-рецептора
|
UA111305C2
(uk)
|
2012-12-21 |
2016-04-11 |
Пфайзер Інк. |
Конденсовані лактами арилу та гетероарилу
|
AR094797A1
(es)
|
2013-02-15 |
2015-08-26 |
Almirall Sa |
Derivados de pirrolotriazina como inhibidores de pi3k
|
SI2958916T1
(sl)
|
2013-02-21 |
2018-11-30 |
Pfizer Inc. |
Trdne oblike selektivnih zaviralcev CDK4/6
|
JO3377B1
(ar)
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
مشتقات بيريدينيل وبيريدينيل مندمج
|
US20160022661A1
(en)
*
|
2013-03-13 |
2016-01-28 |
Ratiopharm Gmbh |
Dosage Form Comprising Crizotinib
|
EP2784083A1
(en)
|
2013-03-28 |
2014-10-01 |
Charité - Universitätsmedizin Berlin |
Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
|
EP2792360A1
(en)
|
2013-04-18 |
2014-10-22 |
IP Gesellschaft für Management mbH |
(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
|
TW201512171A
(zh)
|
2013-04-19 |
2015-04-01 |
Pfizer Ltd |
化學化合物
|
TW201443025A
(zh)
|
2013-04-19 |
2014-11-16 |
Pfizer Ltd |
化學化合物
|
WO2014181213A1
(en)
|
2013-05-10 |
2014-11-13 |
Pfizer Inc. |
Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
|
EP2997084A4
(en)
|
2013-05-17 |
2016-10-12 |
Acupac Packaging Inc |
ANHYDROUS HYDROGEL COMPOSITION
|
RS59018B1
(sr)
|
2013-06-27 |
2019-08-30 |
Pfizer |
Heteroaromatična jedinjenja i njihova upotreba kao dopamin d1 liganada
|
CN104513253A
(zh)
|
2013-10-01 |
2015-04-15 |
南京波尔泰药业科技有限公司 |
用于治疗增殖性疾病的大环化合物
|
WO2015092610A1
(en)
|
2013-12-20 |
2015-06-25 |
Pfizer Limited |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
WO2015092614A1
(en)
|
2013-12-20 |
2015-06-25 |
Pfizer Inc. |
Activating notch alterations in breast cancer
|
WO2015106014A1
(en)
|
2014-01-09 |
2015-07-16 |
Takeda Pharmaceutical Company Limited |
Azaindole derivatives
|
AR099052A1
(es)
|
2014-01-09 |
2016-06-29 |
Takeda Pharmaceuticals Co |
Derivados de azaindol
|
US20170197939A1
(en)
|
2014-04-15 |
2017-07-13 |
Pfizer Inc. |
Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety
|
KR20160142401A
(ko)
|
2014-04-25 |
2016-12-12 |
화이자 인코포레이티드 |
도파민 d1 리간드로서 헤테로방향족 화합물 및 이의 용도
|
MD20160109A2
(ro)
|
2014-04-25 |
2017-04-30 |
Pfizer Inc. |
Compuşi heteroaromatici şi utilizarea lor ca liganzi ai dopaminei D1
|
WO2015162518A1
(en)
|
2014-04-25 |
2015-10-29 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
EP3137454A1
(en)
|
2014-04-28 |
2017-03-08 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
JP6564394B2
(ja)
|
2014-04-28 |
2019-08-21 |
ファイザー・インク |
複素環式化合物およびそのドーパミンd1リガンドとしての使用
|
WO2015170218A1
(en)
|
2014-05-07 |
2015-11-12 |
Pfizer Inc. |
Tropomyosin-related kinase inhibitors
|
MX2016014878A
(es)
|
2014-05-14 |
2017-03-08 |
Pfizer |
Pirazolopiridinas y pirazolopirimidinas.
|
AU2015260906B2
(en)
|
2014-05-15 |
2017-08-31 |
Pfizer Inc. |
Crystalline form of 6-((4R)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl)isoquinoline-1-carbonitrile
|
KR102471082B1
(ko)
|
2014-05-20 |
2022-11-25 |
라퀄리아 파마 인코포레이티드 |
벤즈이소옥사졸 유도체염
|
WO2015181676A1
(en)
|
2014-05-30 |
2015-12-03 |
Pfizer Inc. |
Carbonitrile derivatives as selective androgen receptor modulators
|
CA2950393A1
(en)
|
2014-05-30 |
2015-12-03 |
Pfizer Inc. |
Benzenesulfonamides useful as sodium channel inhibitors
|
WO2015189744A1
(en)
|
2014-06-12 |
2015-12-17 |
Pfizer Limited |
Imidazopyridazine derivatives as modulators of the gabaa receptor activity.
|
CR20160574A
(es)
|
2014-06-17 |
2017-02-23 |
Pfizer |
Compuestos de dihidroisoquinolinona sustituida
|
WO2015193768A1
(en)
|
2014-06-17 |
2015-12-23 |
Pfizer Inc. |
Aryl fused lactams as ezh2 modulators
|
WO2016009296A1
(en)
|
2014-07-16 |
2016-01-21 |
Pfizer Inc. |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
WO2016009303A1
(en)
|
2014-07-17 |
2016-01-21 |
Pfizer Inc. |
Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
|
WO2016009297A1
(en)
|
2014-07-18 |
2016-01-21 |
Pfizer Inc. |
Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
|
WO2016020784A1
(en)
|
2014-08-05 |
2016-02-11 |
Pfizer Inc. |
N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
|
WO2016034971A1
(en)
|
2014-09-04 |
2016-03-10 |
Pfizer Limited |
Sulfonamides derivatives as urat1 inhibitors
|
US10017529B2
(en)
|
2014-09-16 |
2018-07-10 |
BioPharma Works LLC |
Metformin derivatives
|
GB201417163D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
|
GB201417165D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Treatments for Autoimmune Disease
|
WO2016067143A1
(en)
|
2014-10-28 |
2016-05-06 |
Pfizer Inc. |
N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
|
ES2746839T3
(es)
|
2014-12-18 |
2020-03-09 |
Pfizer |
Derivados de pirimidina y triazina y su uso como inhibidores de AXL
|
TW201636342A
(zh)
|
2014-12-19 |
2016-10-16 |
武田藥品工業有限公司 |
煙黴醇衍生物
|
ES2801005T3
(es)
|
2015-01-22 |
2021-01-07 |
Phytoplant Res S L |
Métodos de purificar canabinoides, composiciones y kits asociados
|
WO2016135582A1
(en)
|
2015-02-24 |
2016-09-01 |
Pfizer Inc. |
Substituted nucleoside derivatives useful as anticancer agents
|
US10624972B2
(en)
|
2015-03-13 |
2020-04-21 |
Endocyte, Inc. |
Conjugates for treating diseases
|
WO2016170009A1
(en)
|
2015-04-21 |
2016-10-27 |
Almirall, S.A. |
Amino-substituted heterocyclic derivatives as sodium channel inhibitors
|
PL3302565T3
(pl)
|
2015-06-04 |
2020-06-01 |
Pfizer Inc. |
Stałe postacie dawkowane palbocyklibu
|
CR20180047A
(es)
|
2015-07-31 |
2018-03-07 |
Pfizer |
Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4-hidroxibutan-2-il carbamato como inhibidores de magl
|
WO2017060488A1
(en)
|
2015-10-09 |
2017-04-13 |
Almirall, S.A. |
New trpa1 antagonists
|
WO2017064068A1
(en)
|
2015-10-14 |
2017-04-20 |
Almirall, S.A. |
New trpa1 antagonists
|
EP3386983A1
(en)
|
2015-12-10 |
2018-10-17 |
Pfizer Limited |
4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain
|
EA039213B1
(ru)
|
2015-12-24 |
2021-12-17 |
Такеда Фармасьютикал Компани Лимитед |
Сокристалл, способ его получения и лекарственное средство, содержащее сокристалл
|
US10435388B2
(en)
|
2016-01-07 |
2019-10-08 |
Cs Pharmatech Limited |
Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase
|
WO2017119732A1
(en)
|
2016-01-08 |
2017-07-13 |
Samsung Electronics Co., Ltd. |
Electronic device and operating method thereof
|
MX2018008653A
(es)
|
2016-01-15 |
2018-12-10 |
Pfizer |
Ligandos d3 de dopamina 6,7,8,9-tetrahidro-5h-pirido[2,3-d]azepina .
|
WO2017127073A1
(en)
|
2016-01-20 |
2017-07-27 |
Theravida, Inc. |
Methods and compositions for treating hyperhidrosis
|
CN108884445A
(zh)
|
2016-03-09 |
2018-11-23 |
北京智康博药肿瘤医学研究有限公司 |
肿瘤细胞悬浮培养物和相关方法
|
US20190105407A1
(en)
|
2016-03-31 |
2019-04-11 |
Takeda Pharmaceutical Company Limited |
Isoquinolinyl triazolone complexes
|
CA2969295A1
(en)
|
2016-06-06 |
2017-12-06 |
Pfizer Inc. |
Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
|
US11091483B2
(en)
|
2016-08-12 |
2021-08-17 |
Madera Therapeutics, LLC |
Protein kinase regulators
|
TN2019000039A1
(en)
|
2016-08-15 |
2020-07-15 |
Pfizer |
Pyridopyrimdinone cdk2/4/6 inhibitors
|
US10316021B2
(en)
|
2016-11-28 |
2019-06-11 |
Pfizer Inc. |
Heteroarylphenoxy benzamide kappa opioid ligands
|
JP7273723B2
(ja)
|
2016-12-20 |
2023-05-15 |
オリゴメリックス インコーポレイテッド |
タウオリゴマーの形成を阻害する新規キナゾリノン及びその使用方法
|
WO2018134695A1
(en)
|
2017-01-20 |
2018-07-26 |
Pfizer Inc. |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
|
CA3050853A1
(en)
|
2017-01-23 |
2018-07-26 |
Pfizer Inc. |
Heterocyclic spiro compounds as magl inhibitors
|
US11993625B2
(en)
|
2017-01-24 |
2024-05-28 |
Pfizer, Inc. |
Calicheamicin derivatives and antibody drug conjugates thereof
|
DK3600312T3
(da)
|
2017-03-26 |
2023-07-31 |
Takeda Pharmaceuticals Co |
Piperidinyl- og piperazinylsubstituerede heteroaromatiske carboxamider som modulatorer af gpr6
|
JOP20180057A1
(ar)
|
2017-06-15 |
2019-01-30 |
Takeda Pharmaceuticals Co |
مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
|
SG11201912397RA
(en)
|
2017-06-22 |
2020-01-30 |
Curadev Pharma Ltd |
Small molecule modulators of human sting
|
US11773132B2
(en)
|
2017-08-30 |
2023-10-03 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
Cyclic di-nucleotides as stimulator of interferon genes modulators
|
JP7447002B2
(ja)
|
2017-09-11 |
2024-03-11 |
クルーゾン・ファーマシューティカルズ・インコーポレイテッド |
SHP2のオクタヒドロシクロペンタ[c]ピロールのアロステリック阻害剤
|
TW201920108A
(zh)
|
2017-09-25 |
2019-06-01 |
日商武田藥品工業有限公司 |
N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
|
JP7201400B2
(ja)
|
2017-11-14 |
2023-01-10 |
ファイザー・インク |
Ezh2阻害剤組合せ療法
|
AU2019211188A1
(en)
|
2018-01-29 |
2020-07-30 |
Phytoplant Research S.L. |
Methods of purifying cannabinoids using liquid:liquid chromatography
|
TW201942115A
(zh)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
TW201942116A
(zh)
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌劑之四氫喹唑啉衍生物
|
CA3092003A1
(en)
|
2018-02-27 |
2019-09-06 |
Pfizer Inc. |
Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor
|
TWI834637B
(zh)
|
2018-03-01 |
2024-03-11 |
日商武田藥品工業有限公司 |
六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
|
SG11202009992VA
(en)
|
2018-04-26 |
2020-11-27 |
Pfizer |
2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
|
WO2019243823A1
(en)
|
2018-06-21 |
2019-12-26 |
Curadev Pharma Limited |
Azaheterocyclic small molecule modulators of human sting
|
EP3823723A1
(en)
|
2018-07-19 |
2021-05-26 |
Pfizer Inc. |
Heterocyclic spiro compounds as magl inhibitors
|
WO2020076728A1
(en)
|
2018-10-08 |
2020-04-16 |
Takeda Pharmaceutical Company Limited |
SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
|
US11142525B2
(en)
|
2018-11-15 |
2021-10-12 |
Pfizer Inc. |
Azalactam compounds as HPK1 inhibitors
|
KR20210105955A
(ko)
|
2019-01-23 |
2021-08-27 |
화이자 인코포레이티드 |
공지된 테트라히드로이소퀴놀린 유도체의 모노포스페이트 수화물 염의 다형체 형태
|
CR20210415A
(es)
|
2019-01-31 |
2021-08-26 |
Pfizer |
Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidoria en cdk2
|
US20220125777A1
(en)
|
2019-02-01 |
2022-04-28 |
Pfizer Inc. |
Combination of a cdk inhibitor and a pim inhibitor
|
AU2020228047A1
(en)
|
2019-02-27 |
2021-09-30 |
Madera Therapeutics, LLC |
Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
|
AR118471A1
(es)
|
2019-03-22 |
2021-10-06 |
Takeda Pharmaceuticals Co |
Derivados de pirrol e imidazol fusionados con piridina como inhibidores de ripk2
|
GB201905375D0
(en)
|
2019-04-16 |
2019-05-29 |
Mission Therapeutics Ltd |
Novel compounds
|
GB201905371D0
(en)
|
2019-04-16 |
2019-05-29 |
Mission Therapeutics Ltd |
Novel compounds
|
JOP20210275A1
(ar)
|
2019-04-29 |
2023-01-30 |
Solent Therapeutics Llc |
مشتقات 3-أمينو-4h-بنزو[e][4,2,1]ثيادايازين 1,1-داي أكسيد كمثبطات لـ mrgx2
|
US11339159B2
(en)
|
2019-07-17 |
2022-05-24 |
Pfizer Inc. |
Toll-like receptor agonists
|
KR20220044753A
(ko)
|
2019-07-25 |
2022-04-11 |
큐라데브 파마 프라이버트 리미티드 |
아세틸 조효소 a 신테타제 단쇄 2(acss2)의 소분자 억제제
|
GB201912674D0
(en)
|
2019-09-04 |
2019-10-16 |
Mission Therapeutics Ltd |
Novel compounds
|
MX2022003177A
(es)
|
2019-09-16 |
2022-04-06 |
Takeda Pharmaceuticals Co |
Derivados de piridazin-3(2h)-ona fusionados con azol.
|
EP4103278A1
(en)
|
2020-02-12 |
2022-12-21 |
Curadev Pharma Pvt. Ltd. |
Small molecule sting antagonists
|
TW202146017A
(zh)
|
2020-03-05 |
2021-12-16 |
美商輝瑞股份有限公司 |
間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合
|
AR121683A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
|
AR121682A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
|
JP2021167301A
(ja)
|
2020-04-08 |
2021-10-21 |
ファイザー・インク |
Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置
|
US20230119013A1
(en)
|
2020-04-08 |
2023-04-20 |
Mission Therapeutics Limited |
N-cyanopyrrolidines with activity as usp30 inhibitors
|
IL297838A
(en)
|
2020-05-01 |
2023-01-01 |
Pfizer |
Azalactemic agents and their use as inhibitors of hpk1
|
BR112022022184A2
(pt)
|
2020-05-04 |
2023-01-17 |
Takeda Pharmaceuticals Co |
Derivados de n-(piperidin-4-il)benzamida agindo luminalmente
|
WO2021224818A1
(en)
|
2020-05-08 |
2021-11-11 |
Pfizer Inc. |
Isoindolone compounds as hpk1 inhibitors
|
WO2021239863A1
(en)
|
2020-05-28 |
2021-12-02 |
Mission Therapeutics Limited |
N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction
|
CA3185654A1
(en)
|
2020-06-04 |
2021-12-09 |
Mission Therapeutics Limited |
N-cyanopyrrolidines with activity as usp30 inhibitors
|
JP2023528087A
(ja)
|
2020-06-08 |
2023-07-03 |
ミッション セラピューティクス リミティド |
ミトコンドリア機能不全、癌、及び線維症の治療に使用されるUSP30阻害剤としての1-(5-(2-シアノピリジン-4-イル)オキサゾール-2-カルボニル)-4-メチルヘキサヒドロピロロ[3,4-b]ピロール-5(1H)-カルボニトリル
|
TW202214641A
(zh)
|
2020-06-30 |
2022-04-16 |
美商艾瑞生藥股份有限公司 |
Her2突變抑制劑
|
US20240116937A1
(en)
|
2020-07-15 |
2024-04-11 |
Pfizer Inc. |
Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
|
US20230242539A1
(en)
|
2020-07-15 |
2023-08-03 |
Pfizer Inc. |
Polymorphs of (1S,2S,3S,5R)-3-((6-(Difluoromethyl)-5-Fluoro-1,2,3,4-Tetrahydroisoquinolin-8-YL)OXY)-5-(4-Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-7-YL)Cyclopentane-1,2-DIOL Mono-Hydrochloride
|
CA3189632A1
(en)
|
2020-07-20 |
2022-01-27 |
Pfizer Inc. |
Combination therapy
|
WO2022018667A1
(en)
|
2020-07-24 |
2022-01-27 |
Pfizer Inc. |
Combination therapies using cdk2 and cdc25a inhibitors
|
GB202011812D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
GB202011811D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
EP4196126A1
(en)
|
2020-08-13 |
2023-06-21 |
Pfizer Inc. |
Combination therapy
|
JP7260606B2
(ja)
|
2020-09-15 |
2023-04-18 |
ファイザー・インク |
固体形態のcdk4阻害薬
|
TW202229239A
(zh)
|
2020-09-23 |
2022-08-01 |
日商武田藥品工業股份有限公司 |
作為ripk2抑制劑之3-(6-胺基吡啶-3-基)苯甲醯胺衍生物
|
GB202016800D0
(en)
|
2020-10-22 |
2020-12-09 |
Mission Therapeutics Ltd |
Novel compounds
|
JP2023554521A
(ja)
|
2020-12-22 |
2023-12-27 |
ファイザー・インク |
Eif4e阻害剤の固体形態
|
MX2023007699A
(es)
|
2020-12-24 |
2023-07-10 |
Pfizer |
Formas solidas de un inhibidor cdk2.
|
US11964978B2
(en)
|
2021-03-18 |
2024-04-23 |
Pfizer Inc. |
Modulators of STING (stimulator of interferon genes)
|
AU2022244439A1
(en)
|
2021-03-24 |
2023-09-28 |
Astellas Pharma Inc. |
Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
|
CA3213593A1
(en)
|
2021-03-31 |
2022-10-06 |
Sevenless Therapeutics Limited |
Sos1 inhibitors and ras inhibitors for use in the treatment of pain
|
GB202104609D0
(en)
|
2021-03-31 |
2021-05-12 |
Sevenless Therapeutics Ltd |
New Treatments for Pain
|
CN117545751A
(zh)
|
2021-04-07 |
2024-02-09 |
生命爱科 |
作为ulk1/2抑制剂的2,4-二氨基嘧啶衍生物及其用途
|
WO2022229846A1
(en)
|
2021-04-29 |
2022-11-03 |
Pfizer Inc. |
Treatment of cancer using a transforming growth factor beta receptor type 1 inhibitor
|
CA3225045A1
(en)
|
2021-06-26 |
2022-12-29 |
Array Biopharma Inc. |
Her2 mutation inhibitors
|
WO2023002362A1
(en)
|
2021-07-22 |
2023-01-26 |
Pfizer Inc. |
Treatment of hematological malignancy
|
EP4384268A1
(en)
|
2021-08-11 |
2024-06-19 |
Curadev Pharma Pvt. Ltd. |
Small molecule urea derivatives as sting antagonists
|
WO2023017451A1
(en)
|
2021-08-11 |
2023-02-16 |
Curadev Pharma Pvt. Ltd. |
Small molecule sting antagonists
|
WO2023084459A1
(en)
|
2021-11-15 |
2023-05-19 |
Pfizer Inc. |
Methods of treating sars-cov-2
|
WO2023099561A1
(en)
|
2021-12-01 |
2023-06-08 |
Mission Therapeutics Limited |
Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
|
WO2023099072A1
(en)
|
2021-12-01 |
2023-06-08 |
Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Compounds
|
CA3241001A1
(en)
|
2021-12-02 |
2023-06-08 |
Pfizer Inc |
Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer
|
WO2023187677A1
(en)
|
2022-03-30 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
|
TW202345838A
(zh)
|
2022-04-07 |
2023-12-01 |
日商武田藥品工業股份有限公司 |
稠合噠嗪衍生物
|
TW202410897A
(zh)
|
2022-07-15 |
2024-03-16 |
愛爾蘭商爵士製藥愛爾蘭公司 |
聯芳醚脲化合物
|
WO2024023727A1
(en)
|
2022-07-29 |
2024-02-01 |
Pfizer Inc. |
Novel acc inhibitors
|
WO2024033845A1
(en)
|
2022-08-10 |
2024-02-15 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
WO2024033513A1
(en)
|
2022-08-11 |
2024-02-15 |
Diaccurate |
Compounds for treating cancer
|
WO2024074827A1
(en)
|
2022-10-05 |
2024-04-11 |
Sevenless Therapeutics Limited |
New treatments for pain
|
WO2024105364A1
(en)
|
2022-11-15 |
2024-05-23 |
Curadev Pharma Ltd |
Heterocyclic inhibitors of cdc-like kinases
|